Many patients forgo PCSK9 inhibitors therapy — which is designed to help reduce cholesterol — primarily due to out-of-pocket costs, according to a study published in JAMA Cardiology. For the study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback